High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge

Christopher T. Campbell, Sean R. Llewellyn, Thorsten Damberg, Ian L. Morgan, Marjorie Robert-Guroff, Jeffrey C. Gildersleeve

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Recent progress toward an HIV vaccine highlights both the potential of vaccines to end the AIDS pandemic and the need to boost efficacy by incorporating additional vaccine strategies. Although many aspects of the immune response can contribute to vaccine efficacy, the key factors have not been defined fully yet. A particular area that may yield new insights is anti-glycan immune responses, such as those against the glycan shield that HIV uses to evade the immune system. In this study, we used glycan microarray technology to evaluate anti-glycan antibody responses induced by SIV vaccination and infection in a non-human primate model of HIV infection. This comprehensive profiling of circulating anti-glycan antibodies found changes in anti-glycan antibody levels after both vaccination with the Ad5hr-SIV vaccine and SIV infection. Notably, SIV infection produced generalized declines in anti-glycan IgM antibodies in a number of animals. Additionally, some infected animals generated antibodies to the Tn antigen, which is a cryptic tumor-associated antigen exposed by premature termination of O-linked glycans; however, the Ad5hr-SIV vaccine did not induce anti-Tn IgG antibodies. Overall, this study demonstrates the potential contributions that glycan microarrays can make for HIV vaccine development.

Original languageEnglish
Article numbere75302
JournalPLoS ONE
Volume8
Issue number9
DOIs
StatePublished - 23 Sep 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge'. Together they form a unique fingerprint.

Cite this